Unternehmensübersicht
Sangamo Therapeutics, Inc. operates as a clinical-stage genomic medicine enterprise dedicated to translating scientific discoveries into therapeutic medicines for patients suffering from serious diseases within the United States. The company functions within the Healthcare sector and specifically the Biotechnology industry, where its primary focus is on developing product candidates such as ST-920, a gene therapy product designed to address significant medical needs. The enterprise currently employs 142 individuals and holds a market capitalization of $105.52M, while generating an annual revenue of $39.55M based on trailing twelve-month data. These valuation and revenue figures indicate that the company maintains a small-cap profile typical of early-stage biotechnology firms, reflecting its position as a specialized developer rather than a diversified revenue generator. The limited workforce size relative to the industry suggests a lean operational structure focused on research and development, while the market cap implies a high degree of speculative risk associated with clinical-stage assets that have not yet achieved commercial maturity.
Finanzielle Gesundheit
Sangamo Therapeutics reported a revenue of $39.55M over the trailing twelve months, accompanied by a net income of -$122,932,000 and an EBITDA of -$104,043,000. The substantial divergence between the reported revenue of $39.55M and the negative net income of -$122,932,000 reveals a highly aggressive cost structure characterized by significant operating expenses that exceed total sales, a common characteristic of companies in the clinical development phase. The company generated a free cash flow of -$56,760,500, which indicates that its current financial flexibility is constrained by heavy capital expenditure requirements necessary to advance its product pipeline toward regulatory approval. All three margin metrics present negative figures: a gross margin of -184.9%, an operating margin of -175.5%, and a profit margin of 0.0%, each indicating that the company's core operations are currently loss-making before and after accounting for interest and taxes. The balance sheet shows cash reserves of $20.95M against total debt of $26.80M, resulting in a debt-to-equity ratio listed as N/A, which suggests the company carries more liabilities than liquid cash and operates with a leveraged balance sheet rather than a conservative one. Furthermore, the current ratio stands at 0.84, indicating that the company possesses less than one dollar of current assets for every dollar of current liabilities, which points to potential short-term liquidity pressures. Return on Equity is recorded at -2891.8% and Return on Assets at -83.7%, metrics that reveal management has not yet achieved profitability and that the capital deployed to date has generated negative returns on the invested equity and asset base.
Bewertungsanalyse
The valuation profile includes a P/E Ratio (TTM) of N/A and a forward P/E of 9.55, where the absence of a trailing ratio due to negative earnings contrasts with the forward projection, implying that the market expects a trajectory toward profitability or that earnings are not yet available for standard multiple analysis. The price-to-book ratio is -6.21, a negative figure that indicates the market values the company at a discount relative to its book value, often seen in biotech firms with intangible assets that are not fully captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 2.67 and an EV/EBITDA of -1.07 provide insight into the company's pricing relative to sales volume and earnings before interest, taxes, depreciation, and amortization, suggesting investors are pricing in the potential value of future clinical successes rather than current cash flows. The stock traded between a 52-week high of $0.84 and a 52-week low of $0.21, placing the current trading range within a volatile band that reflects the high uncertainty inherent in clinical-stage development. With a beta of 1.50, the stock exhibits 50% higher volatility than the broader market, indicating that price movements are significantly amplified by general market fluctuations and sector-specific news regarding clinical trial outcomes.
Growth & Income
Sangamo Therapeutics demonstrated a revenue growth rate of 88.4% year-over-year, while the earnings growth rate is N/A due to the company's persistent net losses. The fact that earnings growth is not calculable while revenue expands rapidly implies that top-line growth is currently being fueled by revenue recognition or new partnerships rather than an improvement in the bottom line, suggesting that cost containment or revenue scaling has not yet translated into profitability. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company retains all of its earnings to reinvest into research, development, and clinical trials rather than distributing income to shareholders. This growth and income profile characterizes Sangamo as a capital-intensive entity that prioritizes long-term scientific advancement and pipeline expansion over immediate income generation or shareholder distributions.